Anti-Human CD3 x DLL3 (Tarlatamab) [Clone AMG 757] - 25 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Anti-Human CD3 x DLL3 is a bispecific T-cell engager (BiTE) designed to target CD3 on T-cells and Delta-like ligand 3 (DLL3) on tumor cells. DLL3 is highly expressed in small celllung cancer (SCLC) and other neuroendocrine tumors, making it an attractive target forimmunotherapy. By redirecting T-cells to attack DLL3-expressing tumor cells, this bispecificantibody offers a novel treatment approach for SCLC, a disease known for its poor prognosisand limited therapeutic options. Preclinical studies have demonstrated that DLL3/CD3bispecific antibodies can induce potent, DLL3-dependent T-cell-mediated lysis of tumor cells, recruit T-cells into non-inflamed tumor tissues, and lead to tumor regression in animalmodels. While specific efficacy data for this antibody are not provided, BiTE antibodies havegenerally shown high potency, with some studies indicating efficacy at sub-picomolarconcentrations.1-3. AMG 757, also known as Tarlatamab, is a promising example of a bispecific T-cell engagertargeting DLL3 and CD3 for SCLC treatment. Studies have shown that AMG 757 inducespotent tumor lysis and T-cell activation, resulting in significant tumor regression and evencomplete responses in preclinical models. Clinical trials have reported manageable safetyprofiles with encouraging response durability, including objective response rates of 23.4% to40% and disease control rates of 51.4%. Notably, AMG 757 has demonstrated antitumoractivity with durable responses and promising survival outcomes in patients with previouslytreated SCLC, making it a viable option for targeting DLL3-expressing tumors4-6.

≥ 5.0 mg/ml

The distribution of Anti-Human CD23 x DLL3 in the body includes theblood and lymphatic tissues, where it can effectively engage with both T-cells and tumorcells.